The industry feedback described the strengths and limitations of the NMA 86 and the context around the current treatment landscape. [...] FMEC discussed the daratumumab- publicly available price of daratumumab, and jurisdictions may need containing regimens to consider negotiating further price reductions to improve the cost- in the first- and/or effectiveness of a daratumumab-containing regimen in the first line second-line setting of treatment. [...] daratumumab, based on clinical and cost- effectiveness? Is there sufficient • The clinical efficacy between evidence to support the pomalidomide/bortezomib/dexamethasone and prioritization of carfilzomib/dexamethasone is comparable based on the results from carfilzomib-containing the NMA. [...] • Of note, selinexor was not considered by FMEC in the second-line setting as it was not available at the time of the review nor included at the time of the initiation of the review. [...] 147 This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this 148 document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada 149 applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, 150 Canada.
- Pages
- 9
- Published in
- Canada
